FDA Inspection 1257757 — Antares Pharma, Inc.

Antares Pharma, Inc. — FEI 2182861

The FDA completed an inspection of Antares Pharma, Inc. on January 16, 2025 in Minnetonka, MN. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Drugs.

Inspection Details

Classification
No Action Indicated (NAI) (NAI)
End Date
January 16, 2025
Fiscal Year
2025
Product Type
Drugs
Project Area
Drug Quality Assurance
Location
Minnetonka, MN (United States)